跳至主要内容
临床试验/NL-OMON36434
NL-OMON36434已完成不适用

Assessment of the prognostic value of MM related bone disease as detected by Whole Body X Ray (WBXR), Whole Body - Magnetic Resonance Imaging (WB-MRI) and FluoroDeoxyGlucose - Positron Emission Tomography - Computer Tomography (FDG-PET-CT) at diagnosis (part I) and in follow-up (part II) - Prognostic value of MM bone disease detected by 3 imaging techniques

HOVO0 个研究点目标入组 60 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • Inclusion in the HOVON 87 study, concerning previously untreated patients with symptomatic multiple myeloma, age >65 or younger and ineligible for high dose therapy and peripheral stem cell transplantation.
  • To be included in part II, patients have to participate in part I of the study

排除标准

  • Contraindications for MRI (including e.g. pacemaker, ICD, metallic splinter in eye, hemostatic clips in CNS, claustrofobia, or other implants that are contraindicated according to the MRI operator*s discretion)
  • Physical inability to access either MRI or PET-CT facilities
  • Active, uncontrolled infections
  • Known or suspected hypersensitivity or intolerance to used contrast agents
  • Uncontrolled diabetes
  • Contraindications for (horizontal) immobilization during at least one hour [part II only]

研究者

发起方
HOVO

相似试验